OrbiMed raises $550M to invest in biotechs; Aveo lays out its IPO terms; FDA accepts Arena app;

 @FierceBiotech: Pharma giants Lilly, Merck and Pfizer are joining forces behind Asian cancer research group. Report | Follow @FierceBiotech

 @JohnCFierce: Call me crazy, but in a Termeer/Icahn showdown, I'm giving the edge to Termeer. Follow @JohnCFierce 

> OrbiMed Advisors has raised $550 million for its new health venture fund, its largest ever, according to VentureWire. More than half of that money will be used to invest in biotech companies with 30 percent reserved for medical devices and 10 percent for diagnostics. OrbiMed has been an active player in the biotech space, backing CoGenesys, Cerexa and Peninsula, which all sold for a premium. Altogether the venture group expects to use the money to take stakes in 25 to 30 companies. OrbiMed release

> Aveo Pharmaceuticals is offering up its terms for what it hopes will be a successful IPO. The developer plans to sell at least 7 million shares for $13 to $15 a share, raising up to $86.3 million. The money would be used to fund a Phase III program for the VEGF-inhibitor tivozanib. It's hitting the market at a time that investors appear receptive to new offerings but decidedly realistic about values. Story

> Arena Pharmaceuticals saw its shares jump after the FDA accepted its application for a closely-watched obesity drug. Report

> Shire has won fast-track status for Replagal, its enzyme replacement therapy for Fabry disease. Report

> Poniard Pharmaceuticals has forged a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over 18 months. Poniard release

> A group of bioscience supporters in Colorado have assembled a $4.75 million war chest to help foster new start-ups in the state. Report

> Minerva Biotechnologies has raised at least $1.6 million of a planned $5 million round. Report

And Finally... A team of neuroscientists at the California Institute of Technology, the University of Iowa, the University of Southern California, and the Autonomous University of Madrid have mapped the brain structures that affect general intelligence. Release

Suggested Articles

Just three days after Daiichi Sankyo’s Xospata challenger scored approval in Japan for a form of acute myeloid leukemia, the FDA has declined to clear the drug…

Martin Shkreli settled a lawsuit he filed against his former Retrophin colleagues, claiming they “unceremoniously and illegally” ousted him in 2014.

The appointment ends a 20-year stint at Theravance Biopharma and its parent company that culminated in Sharath Hegde rising to head of research.